Home
January 2010 February 2010 March 2010
Su Mo Tu We Th Fr Sa
Week 5 1 2 3 4 5 6
Week 6 7 8 9 10 11 12 13
Week 7 14 15 16 17 18 19 20
Week 8 21 22 23 24 25 26 27
Week 9 28
Reach urologists

Vardenafil: Efficacy, Tolerability and Future Directions - Abstract Show Comments PDF Print E-mail
  
Friday, 19 June 2009

Urology Service, Walter Reed Army Medical Center, Urology Clinic-4F, 6900 Georgia Avenue, NW, Washington, DC 20307, USA.

This email address is being protected from spam bots, you need Javascript enabled to view it

Vardenafil is a short-acting PDE5 inhibitor used in the treatment of male erectile dysfunction. It is the most potent and specific of the three commercially available PDE5 inhbitors, which may decrease incidence of side effects, although this has not been demonstrated clinically. Although its efficacy in the treatment of erectile dysfunction has been demonstrated in several studies, recent and continuing studies have shown vardenafil's promise as an effective agent in penile rehabilitation, decreasing lower urinary tract symptoms resulting from benign prostatic hyperplasia and management of pulmonary hypertension.

Written by:
Rice KR, Dean RC.   Are you the author?

Reference:
Expert Opin Drug Metab Toxicol. 2009 May;5(5):553-62.
doi:10.1517/17425250902884108

PubMed Abstract
PMID:19416089

UroToday.com Erectile Dysfunction (ED) Section

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 0
PoorBest


 

Bookmark and Share
< Prev   Next >

Member's Section

Login

Sign Up

Quick Search

Meet the Expert


All Experts



Featured Conference

Media and Publisher

Advertising Rates

Working with Industry

Case Studies
Sponsorship Opportunities

Erectile Dysfunction
Sponsored By